NLA Resources
Knowledge Center
Membership Resources
Join the National Lipid Association, focused on enhancing the science and practice of lipidology to promote optimal cardiometabolic health.
After making your filter selections, please scroll down to see results.
Improving Lipid Management for the Acute Coronary Syndrome Patient
Introduction It’s been over 20 years since the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial1 ushered in the initiation of aggressive LDL-C lowering…
How We Do It: Lipid Specialists Pushing Boundaries to Improve Patient Care Across a Variety of Practice Settings
The NLA now includes > 2,000 members with representation from physicians, NP/PAs, clinical pharmacists, dietitians, and other healthcare professionals. In this Clinical Feature, we highlight…
Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association
Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association
Cardiometabolic Syndrome: A Package Deal
Cardiometabolic syndrome, also known as “metabolic syndrome,” refers to a constellation of metabolic abnormalities and cardiovascular risk factors clustered in a given patient. The definitions…
Inflammation in Obesity and Cardiovascular Disease
Obesity is a chronic, relapsing, heterogenous disease characterized by impaired energy regulation and inflammation that leads to cardiometabolic, biomechanical, and psychosocial health consequences. The prevalence…
Adulting: Guidance for Transitioning Patients from Pediatric to Adult Lipid Clinics
The assumption is that patients can engage in self-care and can navigate the healthcare system, thus ensuring a smooth transition. This is an extended process…
Is There a Role for Aspirin in Prevention in 2022?
With recent guideline changes, it is common for clinicians to field questions regarding aspirin therapy. This article is intended to help clinicians apply an individualized…
Case Study: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obesity
Incretins are hormones secreted by intestinal cells in response to the ingestion of glucose and other nutrients. These hormones stimulate pancreatic β cells to secrete…